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IgM Myeloma or Waldenstrom’s
Macroglobulinemia
Is the Big Question?
Vijaya Raj BHATTa; Srujitha MURUKUTLAa; Muniba NAQIa;
Shradha PANTb; Shiksha KEDIAa; Terenig TERJANIANc
a

Department of Medicine, Staten Island University Hospital,
Staten Island, New York, USA
b
Department of Internal Medicine, University of Science and Technology,
Bangladesh, Chittagong
c
Department of Medicine, Division of Hematology and Oncology, Staten Island
University Hospital, Sanford R. Nalitt Institute for Cancer and Blood Related
Diseases, Staten Island, New York, USA

ABSTRACT
Although critical from therapeutic and prognostic perspectives, differentiating IgM Myeloma (MM)
from Waldenstrom’s macroglobulinemia (WM) is fraught with failure. WM can usually be distinguished from IgM MM by the lymphoplasmacytic versus pure plasmacytic morphology, absent versus
present lytic bone lesions, and immunophenotypic findings. However, all these features have their own
limitations; hence, it requires constant vigilance and periodic re-evaluation. Here we describe a case of
a 70-year-old woman initially diagnosed as smoldering IgM MM, who eventually turned out to have
WM.

CASE REPORT

INTRODUCTION

A

lthough critical from therapeutic
and prognostic perspectives, differentiating IgM multiple myeloma
(MM) and Waldenstrom’s macroglobulinemia (WM) is fraught with
failure (1). Here we describe a case of an elderly woman initially diagnosed as smoldering
IgM MM, who eventually turned out to have
WM. 

A

70-year-old woman was referred to hematology-oncology specialty clinic for increased total protein and anemia. The patient
had a history of rheumatoid arthritis diagnosed
one year back and complained of chronic back
pain and multiple joint pains, otherwise she
was asymptomatic. Past medical history was
also significant for depression, irritable bowel
disease, fatty liver, osteoporosis and hypothy-
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roidism. She had undergone 3 caesarean sections and skin cyst removal. Her medications
included escitalopram, levothyroxine, combination of chlordiazepoxide and clidinium,
ibandronate, calcium citrate and vitamin D.
She was started on methotrexate, which was
subsequently discontinued because of transiently elevated transaminases. Family history
was significant for Parkinson’s disease and
breast cancer in mother; history of alcohol
abuse in father, head and neck cancer in uncle
and back tumor in aunt. Her recent mammogram and colonoscopy were normal. She had a
history of 50 pack year smoking but denied
drinking or recreational drug use.
On examination, she had blood pressure of
110/70 mmHg, heart rate of 80/minute, respiratory rate of 20/min and temperature of 99º F.
Fine expiratory wheezes were noted on chest
auscultation. She did not have any petechiae,
bleeding from any site, lymphadenopathy, or
hepatosplenomegaly. Rest of the examination
was unremarkable.
Laboratory test results showed white count
of 4600/μL, haemoglobin of 11.6 g/dl, platelet
count of 137,000/μL, and lactate dehydrogenase of 149 U/L. She had albumin of 3.4 g/dL,
normal glucose, calcium and electrolytes, and
liver and renal function tests. Serum protein
electrophoresis (SPEP) revealed elevated protein of 8.6 g/dl with M-spike of 1.71 g/dl; immunofixation confirmed IgM-kappa monoclonal protein. Further testing demonstrated:
beta-2 microglobulin of 2.6 mcg/ml, serum free
kappa light chain level of 72 mg/L, free lambda
light chain level of 17.9 mg/L and free kappa/
lambda ratio of 4.02, serum viscosity of 2 cP,
serum IgM level of 2247 mg/dl, normal levels
of IgA and IgG and collagen I C-terminal crosslinked telopeptide level of 154 pg/ml. Bone
marrow biopsy examination highlighted normocellular marrow with unremarkable trilineage haematopoiesis and 12% plasma cells.
Flow cytometry determined CD 45 +, CD5-,
CD 10-, CD19-, CD 20-, CD 38+, CD 138+
plasma cells. Immunohistochemistry results illustrated kappa light chain restricted CD138 +
plasma cells with small clusters. Karyotyping
demonstrated a normal 46, XX pattern. Skeletal
survey did not show any osteolytic lesion but
showed osteopenic bones and osteoarthritic
changes in cervical and lumbar spine. Magnetic
resonance imaging (MRI) of thoracic and lumbar confirmed no osteolytic lesion, but mild

facet arthropathy within the lower lumbosacral
spine. Computed tomography (CT) of abdomen and pelvis determined the absence of any
organomegaly.
A diagnosis of smoldering IgM MM was considered primarily based on the bone marrow
findings of CD138+ pure plasma cell dyscrasia
and the absence of typical features of WM
(such as lymphadenopathy, hepatosplenomegaly and hyperviscosity). However, given its rarity and the absence of osteolytic lesions on
skeletal survey, Waldenstrom’s macroglobulinemia was still considered as a possibility. Given
the lack of end-organ dysfunction, the patient
was closely monitored with regular clinical
evaluation as well as monitoring of complete
blood count, comprehensive metabolic panel,
SPEP with immunofixation, LDH, serum IgM
level, free light chain levels and viscosity. The
patient’s clinical and laboratory status remained
to be stable, hence, it was decided not to start
her on any chemotherapy.
Two years later, the patient underwent resection of 0.6 cm intramammary lymph node
which revealed a low grade CD 20 + B-cell
marginal zone lymphoma with fragment of
lymphoid infiltrate with large germinal centers
and increased number of small to intermediate
B-cells, positive for a clonal immunoglobulin
heavy chain (IgH) gene rearrangement. Subsequently, the patient was also found to have a
palpable splenomegaly. CT chest, abdomen
and pelvis showed splenomegaly without enlargement of liver or lymph nodes. Repeat skeletal survey was negative. A repeat bone marrow biopsy done 4 years from the initial visit
showed 5-20% of CD20+/CD138+ small lymphocytes with plasmacytic features with overexpression of kappa light chains scattered
through the marrow with some areas of island
formation. The patient subsequently also developed marginal zone lymphoma over her
right paranasal area. Thus, a diagnosis of slowly
progressing WM (lymphoplasmacytic lymphoma) was established and the patient was treated with Rituximab. One year after the initiation
of Rituximab, the patient is doing well and remains on maintenance therapy. 
DISCUSSION

I

gM MM is extremely rare and accounts for
<0.5% of all MM (2). A large series of patients
with IgM paraprotein had shown that WM was
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the most common cause accounting for nearly
60% of cases whereas MM was not diagnosed
even in a single patient (3). Being such a rare
disease, there is a lack of large-scale studies of
IgM MM with a gap in knowledge about the
sensitive and specific case definition.
The diagnosis of IgM MM currently requires
the presence of IgM monoclonal gammopathy,
≥10% plasma cells on bone marrow biopsy
and lytic bone lesions and/or translocation t
(11;14) (4, 5). This strict definition lacks sensitivity and fails to diagnose a subset of patients
with IgM monoclonal gammopathy with immunophenotypic features suggestive of MM
(5). The diagnosis of WM requires the presence
of IgM monoclonal gammopathy, bone marrow
infiltration by small lymphocytes, plasmacytoid
cells and plasma cells, diffuse, interstitial or
nodular pattern of bone infiltration and surface
Ig+, CD5-, CD10-, CD19+, CD20+, CD23immunophenotype. It is accepted that WM
can be distinguished clinically from IgM myeloma by the lymphoplasmacytic versus pure
plasmacytic morphology, absent versus present
bone involvement, and immunophenotypic
findings (6).
Pure plasmacytic morphology has been
considered a differentiating feature (6); however, its presence in a single bone marrow biopsy may not always be reliable as demonstrated by this case. Although unilateral biopsy has
been shown to be false-negative in significant
percentage of patients with solid tumor, this is
not the case for MM (7) and currently National
Comprehensive Cancer Network guideline recommends unilateral biopsy for both MM and
WM (8). Although it cannot be said with certainty, in retrospect it is possible that the presence of only pure plasma cells in the first bone
marrow biopsy could have been the result of
the sampling error. Therefore, in cases such as
ours, we suggest that repeat or bilateral bone
marrow biopsy be considered. Transformation

of WM to MM (9) or extramedullary plasmacytoma (10) have been described, however, to
our knowledge, there has not been any case
report of transformation of MM to WM and this
seems very unlikely.
The presence of lytic bone lesions and/or
translocation t (11;14) can differentiate between IgM MM and WM, however, these features may be absent in 20 % of cases (11). Myeloma plasma cells are characterized by loss of
CD19, CD27, CD45 along with aberrant expression of CD56, CD20, CD117 and cyclin
D1 (12, 13), although IgM MM is associated
with lower incidence of CD56 expression (13)
and there could be immunophenotypic heterogeneity (14). Even though useful, immunophenotyping of IgM MM and WM can have
significant overlap (15). Thus the suggested differentiating features have limitations.
In our patient, subsequent development of
marginal zone lymphoma and splenomegaly
indicated the possibility of WM, which was
confirmed with repeat bone marrow biopsy.
This case highlights that differentiating IgM MM
from WM can be quite challenging and requires close follow-up and re-assessment. 
CONCLUSION

A

lthough critical from therapeutic and prognostic perspectives, differentiating IgM
MM from WM is fraught with failure. WM can
usually be distinguished from IgM MM by the
lymphoplasmacytic versus pure plasmacytic
morphology, absent versus present bone involvement, and immunophenotypic findings.
However, all these features have their own
limitations; hence, it often requires constant
vigilance and periodic re-evaluation to confirm
the diagnosis.
Conflict of interests: none declared.
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